Foley Partner Paul Broude authored an article titled “The IPO Window Is Opening” in the March 2010 issue of MX: Medtech Executive. Broude examines the reasons for a device company to consider an initial public offering for its growth plans, stating that 2010 may bring the promise of IPOs for medical device companies to fund clinical trials, regulatory approvals, and the protection of the company’s intellectual property. He adds that going public enables some medical device and life science companies to continue growing while creating an exit vehicle for management and other shareholders.
Author(s)
Related Insights
August 15, 2025
Energy Current
Treasury Releases New Beginning of Construction Guidance for Wind and Solar
Treasury and the IRS today released guidance, Notice 2025-42 (the “Notice”), regarding what constitutes beginning of construction for…
August 15, 2025
Health Care Law Today
DOJ Consumer Branch's End Leaves FDA Litigation Questions
With the dissolution of the U.S. Department of Justice's Consumer Protection Branch set to occur by Sept. 30, a vital question that…
August 14, 2025
Foley Ignite
Will the Late Summer M&A Rebound Continue into Fall?
The lazy days of summer seem to be behind us as merger and acquisition (M&A) activity is getting a jump start. A recent article in the…